Amgen (NASDAQ:AMGN) Upgraded at UBS Group

UBS Group upgraded shares of Amgen (NASDAQ:AMGN) to a strong-buy rating in a research report report published on Wednesday morning,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Deutsche Bank Aktiengesellschaft lifted their price objective on Amgen from $280.00 to $285.00 and gave the company a “hold” rating in a research note on Tuesday, November 11th. Bank of America boosted their price objective on Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a report on Friday, September 26th. The Goldman Sachs Group restated a “buy” rating on shares of Amgen in a research report on Tuesday, November 25th. Argus raised their target price on shares of Amgen from $310.00 to $360.00 and gave the company a “buy” rating in a research note on Tuesday, December 30th. Finally, Cantor Fitzgerald lifted their target price on shares of Amgen from $305.00 to $315.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and an average target price of $338.55.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $326.10 on Wednesday. Amgen has a 12 month low of $260.55 and a 12 month high of $346.38. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. The stock has a market cap of $175.60 billion, a P/E ratio of 25.20, a P/E/G ratio of 3.00 and a beta of 0.45. The company has a 50 day moving average of $329.75 and a 200 day moving average of $304.30.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The firm had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The business’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the previous year, the business earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, sell-side analysts forecast that Amgen will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be paid a $2.52 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s payout ratio is currently 73.57%.

Insiders Place Their Bets

In other news, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the sale, the senior vice president owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the transaction, the executive vice president directly owned 41,923 shares in the company, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 10,908 shares of company stock valued at $3,674,966. 0.76% of the stock is currently owned by corporate insiders.

Institutional Trading of Amgen

Institutional investors have recently added to or reduced their stakes in the business. West Family Investments Inc. increased its holdings in shares of Amgen by 1.1% in the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after buying an additional 30 shares during the period. Viawealth LLC grew its position in Amgen by 0.4% during the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after acquiring an additional 30 shares during the last quarter. LOM Asset Management Ltd increased its stake in Amgen by 1.2% in the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock worth $721,000 after purchasing an additional 30 shares during the period. Sittner & Nelson LLC lifted its position in Amgen by 0.4% in the third quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock valued at $2,053,000 after purchasing an additional 30 shares during the last quarter. Finally, TAGStone Capital Inc. lifted its position in Amgen by 0.8% in the third quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after purchasing an additional 32 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: UBS upgraded Amgen (AMGN) to a “strong-buy,” a direct bullish analyst signal that can support the stock. UBS upgrade: Amgen to strong-buy
• Positive Sentiment: Amgen struck an exclusive deal with Disco/Disco Pharma tied to a cancer target (deal worth up to $618M), which strengthens Amgen’s oncology pipeline and future revenue optionality. Amgen Disco oncology pact
• Positive Sentiment: Amgen completed a Phase 1b blinatumomab study in Japan, advancing its leukemia strategy — a clinical progress update that can de-risk a program and support long-term value. Blinatumomab study completed in Japan
• Neutral Sentiment: Truist nudged Amgen’s price target slightly higher (from $318 to $319) but kept a “hold” rating — a mild signal that doesn’t materially change sell-side sentiment. Truist raises AMGN price target to $319
• Neutral Sentiment: Citi reiterated a “hold” on Amgen, indicating continued analyst caution despite pipeline wins. Citi sticks to hold for Amgen
• Neutral Sentiment: Market/sector context: Amgen is tracking with the Nasdaq life-sciences segment and will be in focus at the JPMorgan Healthcare Conference, where peers typically reveal pipeline updates and M&A intent — a neutral-to-positive thematic tailwind depending on conference takeaways. AMGN aligns with Nasdaq life sciences
• Neutral Sentiment: Sector preview: CNBC notes JPMorgan Healthcare will drive pipeline/M&A headlines across big pharmas — Amgen may benefit if it announces high-impact deals. What to expect from pharma at JPM
• Negative Sentiment: Despite the positive deal and clinical updates, shares fell amid a broader market uptick and profit-taking; a Zacks note highlighted recent intraday weakness, reflecting short-term selling pressure. Amgen stock falls amid market uptick

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.